Owner Scorecard


← All companies ← IONQ Manual IOSP → ← INVA Pharmaceuticals IRD →

IONS, Ionis Pharmaceuticals

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.

Latest annual: FY2025 10-K
IONS · Ionis Pharmaceuticals
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$944M
+33.8% YoY · 5% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $874M 5-yr avg $767M
Operating margin −68.0% 5-yr avg −45.3%
ROIC −25% 5-yr avg −21%
Owner-earnings margin −58% 5-yr avg −38%
Free cash flow margin −64% 5-yr avg −40%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has reached 33% at its best but run negative through the cycle (median −17%) on a 98% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Stock-based pay runs about 17% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −11%, above 15% in 1 of 9 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$373M$514M$600M$1.1B$729M$810M$587M$788M$705M$944M$874MRevenueRevenue
$717M$800M$573M$779M$694M$928M$858MGross profitGross prof.
98%99%98%99%98%98%98%Gross marginGross mgn
13%21%41%26%49%23%26%30%38%42%60%SG&A / revenueSG&A/rev
91%72%69%41%73%79%114%128%97%105%R&D / revenueR&D/rev
($20M)$31M($61M)$366M($172M)($30M)($410M)($354M)($475M)($382M)($594M)Operating incomeOp. inc.
−5.4%6.0%−10.2%32.6%−23.6%−3.7%−69.8%−44.9%−67.4%−40.4%−68.0%Operating marginOp. mgn
($84M)($17M)($76M)$339M($135M)($29M)($258M)($334M)($460M)($380M)Pretax incomePretax
($60M)$346K$274M$278M($444M)($29M)($270M)($366M)($454M)($381M)($565M)Net incomeNet inc.
Cash flow & returns
($112M)$174M$603M$346M$36M$31M($274M)($308M)($501M)($269M)($496M)Operating cash flowOp. cash
$7M$7M$11M$13M$13M$15M$14M$10M$10M$10M$12MDepreciationDeprec.
($131M)$81M$187M($92M)$237M($77M)($119M)($57M)($187M)($31M)($107M)Working capital & otherWC & other
$7M$35M$14M$31M$35M$12M$16M$24M$45M$51M$64MCapexCapex
1.9%6.8%2.3%2.8%4.8%1.5%2.7%3.0%6.4%5.5%7.4%Capex / revenueCapex/rev
($119M)$167M$592M$333M$23M$19M($290M)($318M)($511M)($279M)($509M)Owner earningsOwner earn.
−32.0%32.6%98.8%29.7%3.1%2.3%−49.4%−40.3%−72.4%−29.5%−58.2%Owner earnings marginOE mgn
($119M)$139M$589M$315M$772K$19M($290M)($331M)($546M)($320M)($561M)Free cash flowFCF
−32.0%27.1%98.3%28.0%0.1%2.3%−49.4%−42.1%−77.5%−33.9%−64.2%Free cash flow marginFCF mgn
$0$0$34M$91M$0$0BuybacksBuybacks
$57M($358M)($930M)($41M)$274M$195M($263M)($214M)($134M)($278M)Investing cash flowInv. cash
$11M$229M$476M$100M($597M)$246M($55M)$644M$478M$676MFinancing cash flowFin. cash
($18K)$93K$617K($111K)($418K)$352K($273K)Exchange-rate effectFX
($44M)$45M$149M$404M($286M)$472M($593M)$123M($157M)$130MChange in cashΔ cash
-3%4%-4%20%-11%-22%-23%-24%-16%-25%ROICROIC
-61%0%26%19%-60%-4%-47%-95%-77%-78%-129%Return on equityROE
−61%0%26%19%−60%−4%−47%−95%−77%−78%−129%Retained to equityRetained/eq
Balance sheet
$85M$130M$279M$683M$398M$2.1B$2.0B$2.3B$2.3B$2.7B$2.1BCash & investmentsCash+inv
$10M$9M$18M$22M$25M$22M$7M$13M$10M$51MInventoryInvent.
$21M$25M$29M$16M$17M$12M$18M$26M$43M$28M$48MAccounts payablePayables
($15M)($20M)$2M$5M$13M$4M($19M)($30M)($18M)$3MOperating working capitalOper. WC
$798M$1.2B$2.2B$2.7B$2.1B$2.3B$2.2B$2.6B$2.6B$3.0B$2.5BCurrent assetsCur. assets
$134M$244M$280M$273M$599M$241M$312M$448M$309M$782M$316MCurrent liabilitiesCur. liab.
6.0×4.8×7.9×10.0×3.6×9.7×7.1×5.9×8.5×3.8×7.9×Current ratioCurr. ratio
$93M$122M$132M$154M$181M$178M$74M$71M$94M$123MNet PP&ENet PP&E
$912M$1.3B$2.7B$3.2B$2.4B$2.6B$2.5B$3.0B$3.0B$3.5B$3.0BTotal assetsAssets
$501M$533M$568M$788M$840M$1.2B$1.2B$1.2B$1.8B$1.8BTotal debtDebt
$416M$403M$289M$104M$442M($811M)($1.1B)($1.1B)($917M)($294M)Net debt / (cash)Net debt
-0.5×0.7×-1.4×29.4×-18.1×-3.2×-50.5×-27.9×-28.0×-22.1×-31.6×Interest coverageInt. cov.
$813M$957M$1.5B$1.5B$1.6B$1.8B$2.0B$2.6B$2.4B$3.0BTotal liabilitiesTotal liab.
$0$84M$139M$213MNoncontrolling interestsNCI
$100M$281M$1.0B$1.5B$743M$772M$573M$387M$588M$489M$440MShareholders’ equityEquity
19.3%16.7%21.9%13.1%31.6%14.9%17.1%13.4%18.5%14.2%18.7%Stock comp / revenueSBC/rev
Per share
121M126M134M153M140M141M142M143M150M160M165MShares out (diluted)Shares
$3.08$4.08$4.47$7.33$5.22$5.75$4.14$5.50$4.72$5.90$5.29Revenue / shareRev/sh
$-0.50$0.00$2.04$1.82$-3.18$-0.20$-1.90$-2.56$-3.04$-2.38$-3.42EPS (diluted)EPS
$-0.99$1.33$4.42$2.17$0.16$0.13$-2.05$-2.22$-3.41$-1.74$-3.08Owner earnings / shareOE/sh
$-0.99$1.11$4.40$2.05$0.01$0.13$-2.05$-2.31$-3.65$-2.00$-3.40Free cash flow / shareFCF/sh
$0.06$0.28$0.10$0.20$0.25$0.08$0.11$0.17$0.30$0.32$0.39Cap. spending / shareCapex/sh
$0.82$2.23$7.82$9.60$5.32$5.47$4.04$2.70$3.94$3.06$2.66Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+7.5%/yr+2.5%/yr
Capital spending / share+20.8%/yr+5.0%/yr
Book value / share+15.7%/yr−10.5%/yr

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2017FY2021

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned ($279M) of owner earnings, the operating cash left after the $10M it takes just to hold its position. It put $41M more into growth; free cash flow, after that spending, was ($320M).

FY2025FY2024FY2023FY2022FY2021
Reported net income($381M)($454M)($366M)($270M)($29M)
Depreciation & amortizationnon-cash charge added back+$10M+$10M+$10M+$14M+$15M
Stock-based compensationreal costnon-cash, but a real cost+$134M+$130M+$106M+$100M+$121M
Working capital & othertiming of cash in and out, other non-cash items−$31M−$187M−$57M−$119M−$77M
Cash from operations($269M)($501M)($308M)($274M)$31M
Maintenance capital expenditurethe spending needed just to hold position and volume−$10M−$10M−$10M−$16M−$12M
Owner earnings($279M)($511M)($318M)($290M)$19M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$41M−$36M−$14M
Free cash flow($320M)($546M)($331M)($290M)$19M
Owner-earnings marginowner earnings ÷ revenue-30%-72%-40%-49%2%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $10M, roughly its depreciation, the rate its assets wear out). The other $41M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $134M), owner earnings is nearer ($412M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($382M) ÷ interest expense $17M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $372M + ST investments $2.3B − debt $1.8B
    What this means

    Cash and short-term investments exceed every dollar of debt by $917M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average through the cycle
    9-yr median, range -24%–20%; -16% latest = NOPAT ($302M) ÷ invested capital $1.9B
    Industry peers: median -1%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 9 years (it ran -16% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Consumes cash through the cycle
    10-yr median margin, range -72%–99%; latest ($279M) = operating cash ($269M) − maintenance capex $10M
    Industry peers: median 1%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -30% of revenue this year, a -14% median across 10 years. It chose to put $41M more into growth, so free cash flow this year was ($320M) — the gap is investment, not weakness. Treating stock comp as the real expense it is (less $134M of SBC) leaves ($412M).

  • Loss, and burning cash
    Net income ($381M) · cash from operations ($269M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 5.14×
    Expanding
    Capex $51M ÷ depreciation $10M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 14.2%
    The count is rising
    Stock compensation $134M (fiscal 2025), 14.2% of revenue · no repurchases · diluted shares +12.8% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $944M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 3.83×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $1.8B vs $2.2B WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 7 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth Miss
    Earnings +33% over the record · −662%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-2.41/share (latest year $-2.29), the averaged base the calculator's gate runs on, and book value is $2.94/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 3 of 10
    What this means

    Lost money in 7 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 1 of 9 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −3% → −51% (3-yr avg ends)
    What this means

    Through the cycle the operating margin slipped — about −3% early to −51% lately, median −24% — competition or costs are biting in.

  • Reinvestment, incremental ROIC −43%
    What this means

    Reinvested capital came back at a negative incremental return over this window — the invested base grew while operating profit did not. The filings show where it went.

  • Worst year 2022 · −69.8% op. margin
    What this means

    Operations went underwater in 2022, understand why before trusting the good years.

  • Share count +3.2%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$2.5B
  • Cash & short-term investments$2.1B
  • Inventory$51M
  • Other current assets$386M
Current liabilities$316M
  • Debt due within a year$432M
  • Accounts payable$48M
Current ratio7.89×all current assets ÷ what's due · Graham looked for 2×
Quick ratio7.73×stricter: inventory excluded
Cash ratio6.51×strictest: cash alone against what's due
Working capital$2.2Bthe cushion left after near-term bills
Debt due this year vs. cash$432M due · $2.1B cash covered by cash on hand, no refinancing forced · both figures from the Jun 30, 2026 balance sheet
Cash runway3.7 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago−40.7%the freshest read on whether the business is still growing
Current ratio, recent quarters8.9× → 7.9×
Deeper floors
Tangible book value$410Mequity stripped of goodwill & intangibles
Net current asset value($63M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$2.0B$272M of it operating leases
Deferred revenue$137Mcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Dr. Monia$13.3M−$2.6M$19M
2022Dr. Monia$7.3M$9.5M($290M)
2023Dr. Monia$12.5M$14.2M($318M)
2024Dr. Monia$15.4M−$2.7M($511M)
2025Dr. Monia$13.4M$42.6M($279M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership1.8%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • CEO pay ratio44:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$134M

    The slice of the business handed to employees in shares in fiscal 2025, 14.2% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition, Income taxes as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
LEGNLegend Biotech Corporation$1.0B55%-198.6%-125%-143%
MDGLMadrigal Pharmaceuticals Inc.$958M-153.9%2y-61%-137%2y
IONSIonis Pharmaceuticals$944M98%-16.9%-11%-14%
EVOEvotec SE$917M24%4.7%-1%1%
ANIPANI Pharmaceuticals Inc.$883M62%8.8%4%17%
HRMYHarmony Biosciences Holdings Inc.$868M79%27.1%38%33%
ARWRArrowhead Pharmaceuticals$829M-95.5%-51%-64%
TLXTelix Pharmaceuticals Limited$804M63%3.7%18%3%
Group median63%-6.6%-6%-6%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Ionis Pharmaceuticals is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered3%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−64%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Ionis Pharmaceuticals (IONS), the owner's record," https://ownerscorecard.com/c/IONS, data as of 2026-07-18.

Manual order: ← IONQ its page in the Manual IOSP →

Industry order: ← INVA the Pharmaceuticals chapter IRD →